Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7322
    +0.0025 (+0.34%)
     

  • CRUDE OIL

    83.79
    +0.98 (+1.18%)
     

  • Bitcoin CAD

    88,460.13
    +952.57 (+1.09%)
     

  • CMC Crypto 200

    1,397.22
    +14.65 (+1.06%)
     

  • GOLD FUTURES

    2,344.50
    +6.10 (+0.26%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ

    15,611.76
    -100.99 (-0.64%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6822
    +0.0003 (+0.04%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, DOWNBEAT GDP

Caterpillar sinks 7% after earnings, management sees weakness in Europe, Asia-Pacific

New Strong Sell Stocks for October 14th

Zacks Equity Research
·2 min read

Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:

Arconic Corporation ARNC is a provider of aluminum sheet, plate and extrusions, as well as architectural products to transportation, aerospace, industrial, packaging and building and construction markets. The Zacks Consensus Estimate for its current year earnings has been revised 2.6% downward over the last 30 days.

Bassett Furniture Industries, Incorporated BSET is a manufacturer and marketer of high quality, mid-priced home furnishings. The Zacks Consensus Estimate for its current year earnings has been revised 1.1% downward over the last 30 days.

Fresenius Medical Care AG & Co. KGaA FMS is a provider of dialysis care and related services. The Zacks Consensus Estimate for its current year earnings has been revised 0.5% downward over the last 30 days.

ADVERTISEMENT

Ocular Therapeutix, Inc. OCUL is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Zacks Consensus Estimate for its current year earnings has been revised 18.6% downward over the last 30 days.

Protagonist Therapeutics, Inc. PTGX is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Zacks Consensus Estimate for its current year earnings has been revised nearly 0.4% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report
 
Ocular Therapeutix, Inc. (OCUL) : Free Stock Analysis Report
 
Bassett Furniture Industries, Incorporated (BSET) : Free Stock Analysis Report
 
Arconic Corporation (ARNC) : Free Stock Analysis Report
 
Protagonist Therapeutics, Inc. (PTGX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research